Literature DB >> 7551221

MF59. Design and evaluation of a safe and potent adjuvant for human vaccines.

G Ott1, G L Barchfeld, D Chernoff, R Radhakrishnan, P van Hoogevest, G Van Nest.   

Abstract

MF59 is a safe, practical, and potent adjuvant for use with human vaccines. The formulation is easily manufactured, may be sterilized by filtration, and is both compatible and efficacious with all antigens tested to date. MF59 has been shown to be a potent stimulator of cellular and humoral responses to subunit antigens in both animal models and clinical studies. Toxicology studies in animal models and Phase I-III studies in humans have demonstrated the safety of MF59 with HSV, HIV, and influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551221     DOI: 10.1007/978-1-4615-1823-5_10

Source DB:  PubMed          Journal:  Pharm Biotechnol        ISSN: 1078-0467


  71 in total

1.  Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.

Authors:  T Menegon; V Baldo; C Bonello; D Dalla Costa; A Di Tommaso; R Trivello
Journal:  Eur J Epidemiol       Date:  1999-07       Impact factor: 8.082

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 3.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-07-19       Impact factor: 3.641

5.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

6.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Authors:  Grazia Galli; Duccio Medini; Erica Borgogni; Luisanna Zedda; Monia Bardelli; Carmine Malzone; Sandra Nuti; Simona Tavarini; Chiara Sammicheli; Anne K Hilbert; Volker Brauer; Angelika Banzhoff; Rino Rappuoli; Giuseppe Del Giudice; Flora Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 7.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

8.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

9.  Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D.

Authors:  W C Manning; X Paliard; S Zhou; M Pat Bland; A Y Lee; K Hong; C M Walker; J A Escobedo; V Dwarki
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 10.  Biomimetic nanoparticles: preparation, characterization and biomedical applications.

Authors:  Ana Maria Carmona-Ribeiro
Journal:  Int J Nanomedicine       Date:  2010-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.